Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

医学 奥拉帕尼 卵巢癌 BRCA突变 临床终点 内科学 肿瘤科 安慰剂 癌症 生活质量(医疗保健) 实体瘤疗效评价标准 临床试验 无进展生存期 进行性疾病 化疗 病理 生物化学 化学 基因 替代医学 护理部 聚合酶 聚ADP核糖聚合酶
作者
Michael Friedländer,Kathleen N. Moore,Nicoletta Colombo,Giovanni Scambia,Byoung‐Gie Kim,Ana Oaknin,Alla Lisyanskaya,Gabe S. Sonke,Charlie Gourley,Susana Banerjee,Amit M. Oza,Antonio González-Martı́n,Carol Aghajanian,William H. Bradley,Joyce F. Liu,Cara Mathews,Frédèric Selle,Alain Lortholary,Elizabeth Lowe,Robert Hettle
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (5): 632-642 被引量:54
标识
DOI:10.1016/s1470-2045(21)00098-x
摘要

Background In the phase 3 SOLO1 trial, maintenance olaparib provided a significant progression-free survival benefit versus placebo in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation in response after platinum-based chemotherapy. We analysed health-related quality of life (HRQOL) and patient-centred outcomes in SOLO1, and the effect of radiological disease progression on health status. Methods SOLO1 is a randomised, double-blind, international trial done in 118 centres and 15 countries. Eligible patients were aged 18 years or older; had an Eastern Cooperative Oncology Group performance status score of 0–1; had newly diagnosed, advanced, high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer with a BRCA mutation; and were in clinical complete or partial response to platinum-based chemotherapy. Patients were randomly assigned (2:1) to either 300 mg olaparib tablets or placebo twice per day using an interactive voice and web response system and were treated for up to 2 years. Treatment assignment was masked for patients and for clinicians giving the interventions, and those collecting and analysing the data. Randomisation was stratified by response to platinum-based chemotherapy (clinical complete or partial response). HRQOL was a secondary endpoint and the prespecified primary HRQOL endpoint was the change from baseline in the Functional Assessment of Cancer Therapy–Ovarian Cancer Trial Outcome Index (TOI) score for the first 24 months. TOI scores range from 0 to 100 (higher scores indicated better HRQOL), with a clinically meaningful difference defined as a difference of at least 10 points. Prespecified exploratory endpoints were quality-adjusted progression-free survival and time without significant symptoms of toxicity (TWiST). HRQOL endpoints were analysed in all randomly assigned patients. The trial is ongoing but closed to new participants. This trial is registered with ClinicalTrials.gov, NCT01844986. Findings Between Sept 3, 2013, and March 6, 2015, 1084 patients were enrolled. 693 patients were ineligible, leaving 391 eligible patients who were randomly assigned to olaparib (n=260) or placebo (n=131; one placebo patient withdrew before receiving any study treatment), with a median duration of follow-up of 40·7 months (IQR 34·9–42·9) for olaparib and 41·2 months (32·2–41·6) for placebo. There was no clinically meaningful change in TOI score at 24 months within or between the olaparib and placebo groups (adjusted mean change in score from baseline over 24 months was 0·30 points [95% CI −0·72 to 1·32] in the olaparib group vs 3·30 points [1·84 to 4·76] in the placebo group; between-group difference of −3·00, 95% CI −4·78 to −1·22; p=0·0010). Mean quality-adjusted progression-free survival (olaparib 29·75 months [95% CI 28·20–31·63] vs placebo 17·58 [15·05–20·18]; difference 12·17 months [95% CI 9·07–15·11], p<0·0001) and the mean duration of TWiST (olaparib 33·15 months [95% CI 30·82–35·49] vs placebo 20·24 months [17·36–23·11]; difference 12·92 months [95% CI 9·30–16·54]; p<0·0001) were significantly longer with olaparib than with placebo. Interpretation The substantial progression-free survival benefit provided by maintenance olaparib in the newly diagnosed setting was achieved with no detrimental effect on patients' HRQOL and was supported by clinically meaningful quality-adjusted progression-free survival and TWiST benefits with maintenance olaparib versus placebo. Funding AstraZeneca and Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
腼腆的寒风完成签到 ,获得积分10
刚刚
Lily发布了新的文献求助10
刚刚
1秒前
shark发布了新的文献求助10
1秒前
1秒前
慕青的应助被277采纳,获得10
1秒前
ww发布了新的文献求助10
2秒前
上官天宇发布了新的文献求助10
2秒前
2秒前
yxb完成签到 ,获得积分20
3秒前
wanci的应助被钟梓袄采纳,获得10
4秒前
秋风的应助被钟梓袄采纳,获得10
4秒前
顾矜的应助被钟梓袄采纳,获得10
4秒前
领导范儿的应助被钟梓袄采纳,获得10
4秒前
香蕉觅云的应助被0911采纳,获得10
4秒前
嘻嘻哈哈发布了新的文献求助210
4秒前
卓矢完成签到 ,获得积分10
5秒前
苹果初阳完成签到,获得积分10
6秒前
8秒前
明理含之发布了新的文献求助50
8秒前
8秒前
9秒前
传奇3的应助被坚强孤容采纳,获得10
9秒前
9秒前
10秒前
10秒前
彩色的冬日完成签到 ,获得积分10
12秒前
充电宝的应助被qwer123456采纳,获得10
12秒前
yyy完成签到,获得积分10
12秒前
277发布了新的文献求助10
12秒前
从南到北发布了新的文献求助10
13秒前
lawrencewong发布了新的文献求助10
13秒前
哈哈哈发布了新的文献求助10
14秒前
昵称吧发布了新的文献求助10
14秒前
14秒前
cdercder的应助被July采纳,获得30
16秒前
20完成签到,获得积分10
17秒前
银月葱头完成签到,获得积分10
17秒前
Ava的应助被Lily采纳,获得10
17秒前
Fei完成签到,获得积分10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Improving the wear resistance of vehicle gear oil by oil soluble LaF3 nanoparticles and typical additives of gear oil 500
Boundaries and Bodhisattvas 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8183204
求助须知:如何正确求助?哪些是违规求助? 9572434
关于积分的说明 21825655
捐赠科研通 7779988
什么是DOI,文献DOI怎么找? 3433852
关于科研通互助平台的介绍 2558060
邀请新用户注册赠送积分活动 2480148